Bioxytran Inc
OTC:BIXT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Altamin Ltd
ASX:AZI
|
AU |
|
X
|
XL Fleet Corp
F:XLF
|
US |
|
C
|
Crunchfish AB
STO:CFISH
|
SE |
|
C
|
CS Group SA
XBER:L8O
|
FR |
|
Modern Land (China) Co Ltd
HKEX:1107
|
CN |
|
A
|
Ageson Bhd
KLSE:AGES
|
MY |
|
J
|
Julong Holding Ltd
NASDAQ:JLHL
|
CN |
|
Bank Nationalnobu Tbk PT
IDX:NOBU
|
ID |
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Bioxytran Inc
OTC:BIXT
|
3.8m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
384.5B USD |
Loading...
|
|
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
362.4B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
189.6B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.4B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.7B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
67.9B AUD |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
Other Profitability Ratios
Bioxytran Inc
Glance View
BioXyTran, Inc. engages in the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans, which is a lack of oxygen in tissues. The company is headquartered in Needham, Massachusetts. The company went IPO on 2010-01-05. The Company’s lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with an intended application that includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiaries, provides lead pharmaceutical drug candidate, ProLectin-Rx. ProLectin-Rx is a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, which is a type of galectin.
